Gen9 Chief Legal Officer Jennifer Camacho has been appointed by the U.S. Secretary of Commerce to the Patent Public Advisory Committee (PPAC) of the U.S. Patent and Trademark Office (USPTO). The PPAC was created by statute to advise the Under Secretary of Commerce for Intellectual Property and Director of the USPTO on the management of patent operations.

As part of the nine-member PPAC, Ms. Camacho will provide guidance on matters of the organization’s policies, goals, budget and performance. “I am honored to serve our country in this capacity,” said Ms. Camacho. “It is a privilege to join the committee in advising the USPTO which plays a critical role in our economic growth by protecting innovation and advancements in technology.”

“We’re thrilled by the news of Jennifer’s appointment to the PPAC,” said Kevin Munnelly, President and CEO of Gen9. “Her wealth of experience has been a true asset to Gen9 in building our world-class patent estate. She has invaluable insight to contribute to the USPTO.”

Prior to joining Gen9, Ms. Camacho was a partner in the international law firms of Proskauer Rose, LLP and Greenberg Traurig, LLP where she represented multiple clients in the life sciences industry, including biotechnology and synthetic biology companies, pharmaceutical and medtech companies, investment banks, venture capital firms and other industry stakeholders. Ms. Camacho has been recognized for her work in the fields of intellectual property and life sciences law and has received multiple awards and honors, including the Tech Luminary and Innovation All-Star Award from the Boston Business Journal and Mass High Tech. She received her bachelor’s degree in Cell and Structural Biology from the University of Illinois, and her law degree from Boston College Law School.

For more information on Gen9, please visit http://www.gen9bio.com/.

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.